This Collaborative Project involves seven partners from four different European countries and is related to the theme HEALTH.2010.2.4.4-1: Clinical development of substances with a clear potential as orphan drugs. The AIPGENE project is co-funded by the European Commission within the 7th Framework Programme for Research. The project is co-ordinated by CIMA, a European Center for Applied Medical Research, started in 2004.
AIPGENE is a collaborative project which aims to develop the clinical use of the orphan drug AAV5-AAT-PBGD for the treatment of the rare disease AIP. The completion of this project will represent an important advance in the clinical management, physiopathology and therapy of metabolic liver diseases. The international team of experts involved in the AIPgene consortium brings together complementary scientific disciplines to implement a new therapeutic option for AIP patients.
AIPGene in Clinicaltrials.gov.Know more..